Nvidia is no longer removing stock-based compensation expenses from its adjusted earnings per share calculation.

Certain books refuse to leave your assumptions intact. They question how democracies survive, how the media shape public ...

Discusses Sale of Hearing Business to Amplifon and Strategic Refocus on Technology Innovation March 16, 2026 7:00 AM ...

CytomX Therapeutics, Inc. upgraded to speculative Buy on Varseta-M mCRC data. Click for this updated look at CTMX stock and see why I am now bullish.

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...

Canada produces promising digital health tools, but a new report says procurement barriers and fragmented systems hold them ...

Explore the fascinating intersection of sfumato and chiaroscuro, where messy brushstrokes reveal the true genius of the Old Masters ...

Quest Resource Holding Corporation stated that, "pipeline remains very healthy," but conversion timelines are delayed due to macroeconomic uncertainty. CEO Perry W. Moss emphasized that operational ...

A conversation with Sir Stephen Fry is a whirlwind of eclectic and esoteric references across a staggering diversity of knowledge that is stochastically connected in his polymathic mind to produce ...

Pressure washers have endless uses, from cleaning your car or bike to the patio, the gutters, a well used barbecue, dusty garden chairs and even your windows. Some even use them to clean carpets and ...

Our new Magna Carta would protect the rule of law, universal human rights and trial by jury. Freedom of expression, a free ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.